Given that current proteasome inhibitors primarily target the β5/PSMB5 subunit, researchers have developed a β2/PSMB7-specific inhibitor, which has demonstrated the ability to sensitize cancer cells to β5/PSMB5 inhibition 121, 122. Here, PSMB5 is linked to cancer.